Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 16, Number 9—September 2010
Research

Pediatric Pneumococcal Serotypes in 4 European Countries

Germaine Hanquet1Comments to Author , Esther Kissling, Asuncion Fenoll, Robert C. George, Agnes Lepoutre, Tinne Lernout, David Tarragó, Emmanuelle Varon, and Jan Verhaegen
Author affiliations: Author affiliations: Scientific Institute of Public Health, Brussels, Belgium (G. Hanquet, E. Kissling, T. Lernout); Belgian Knowledge Centre, Brussels (G. Hanquet); Instituto de Salud Carlos III, Madrid, Spain (A. Fenoll, D. Tarragó,); Health Protection Agency, London, UK (R. George); Institut de Veille Sanitaire, Saint Maurice, France (A. Lepoutre); Hôpital Européen G. Pompidou, Paris, France (E. Varon); Katholieke Universiteit Leuven Pneumococcus Reference Laboratory, Leuven, Belgium (J. Verhaegen)

Main Article

Table 1

Cases of invasive pneumococcal disease, underreporting rates, and numbers adjusted for underreporting among children <15 years of age, 4 European countries, 1996–2006*

Country/epidemiologic year Total typed Underreporting, %† Total adjusted‡ Serotype
PCV7 types NVT 1 7F 19A
Spain
1996–97 155 18 869 544 325 62 0 28
1997–98 179 19 919 590 329 41 15 5
1998–99 191 26 740 415 326 81 16 31
1999–00 211 30 713 463 250 88 7 20
2000–01 252 28 901 580 322 107 11 54
2001–02 301 30 1,014 613 401 91 3 44
2002–03 426 39 1,092 528 564 131 31 97
2003–04 434 45 959 433 526 106 22 128
2004–05 528 43 1,228 367 860 207 70 198
2005–06
 493
 42
 1,185
 288
 896
 312
 74
 168
Belgium
1996–97 160 44 363 225 138 34 7 11
1997–98 202 46 436 272 165 32 9 32
1998–99 185 55 339 179 159 31 7 29
1999–00 197 55 356 218 138 40 5 23
2000–01 256 56 455 293 162 52 11 32
2001–02 295 65 454 268 186 48 11 32
2002–03 370 75 497 283 214 66 15 42
2003–04 382 73 521 270 251 91 20 42
2004–05 437 76 578 315 263 103 22 45
2005–06
 378
 75
 506
 190
 316
 102
 37
 58
France
1996–97 258 33 773 547 226 52 0 40
1997–98 NA NA NA NA NA NA NA NA
1998–99 NA NA NA NA NA NA NA NA
1999–00 NA NA NA NA NA NA NA NA
2000–01 NA NA NA NA NA NA NA NA
2001–02 320 41 775 497 278 64 15 53
2002–03 399 46 864 531 333 92 32 87
2003–04 384 47 811 424 387 119 23 90
2004–05 438 54 806 359 447 159 41 71
2005–06
 389
 50
 774
 277
 497
 157
 62
 93
England and Wales
1996–97 378 60 630 315 315 45 13 13
1997–98 429 62 689 462 226 43 14 26
1998–99 438 67 654 473 181 24 10 16
1999–00 429 64 666 453 213 36 8 37
2000–01 518 71 735 562 173 37 23 21
2001–02 557 72 770 549 221 37 14 28
2002–03 541 67 804 579 224 37 24 30
2003–04 627 71 889 628 261 67 16 37
2004–05 672 74 914 590 324 114 20 39
2005–06 775 76 1,014 640 374 139 38 38

*PCV7, heptavalent pneumococcal conjugate vaccine; PCV7 types, serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F; NVT, non-PCV7 vaccine serotypes, i.e., serotypes not included in the PCV7 vaccine; NA, not available.
†Underreporting rate = number of cases for which an isolate was typed at the national reference laboratory on the total number of laboratory-confirmed invasive pneumococcal cases estimated in the country (by capture–recapture or other methods) in children <15 years of age.
‡The sum of PCV7 types and NVT cases may slightly differ from the total adjusted because of rounding.
§Data have been adjusted for ascertainment and for the distribution of blood/cerebrospinal fluid isolates.

Main Article

1Current affiliation: Belgian Healthcare Agency, Brussels, Belgium.

Page created: August 28, 2011
Page updated: August 28, 2011
Page reviewed: August 28, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external